Telix Quarterly Results and Investor Call / Webcast Notification
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 September 2023 on Wednesday 18 October…
Read moreNews & Views
HRH Princess Astrid of Belgium visits Telix’s New European Manufacturing Facility in Brussels South
News,
Telix has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company’s recently inaugurated production facility, in Brussels South (Seneffe) in the Wallonia region…
Read more
Telix collaborates with Eckert & Ziegler and RefleXion Medical to Expand Treatment Options for Prostate Cancer Patients
News,
Telix, Eckert & Ziegler, and RefleXion Medical today announced a comprehensive collaboration agreement to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling,…
Read more
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 –…
Read more
Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers
Read more
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise…
Read more
Telix Half-Year Results 2023 and Investor Call / Webcast Notification
Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August…
Read more
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), for the…
Read more
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
Telix today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard…
Read more
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise…
Read more